NASDAQ:TCON - Nasdaq - US89237H3084 - Common Stock - Currency: USD
1.43
-0.02 (-1.38%)
The current stock price of TCON is 1.43 USD. In the past month the price decreased by -5.3%. In the past year, price decreased by -75.43%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. The company is headquartered in San Diego, California and currently employs 18 full-time employees. The company went IPO on 2015-01-30. The firm is focused on the development and commercialization of targeted therapeutics for cancer. The Company’s lead product candidate, envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma. The Company’s other product candidates are YH001, a CTLA-4 antibody that is in Phase I/II development for the treatment of sarcoma; TRC102, a small molecule that is in Phase II clinical development for the treatment of mesothelioma; TJ004309, a CD73 antibody that is in Phase I testing, that is being developed through a collaboration with I-Mab Biopharma, and multiple bispecific antibody programs in preclinical development that are being developed through a collaboration with I-Mab Biopharma. The firm offers partners a solution for the clinical development and commercialization of their products in the United States.
TRACON PHARMACEUTICALS INC
4350 La Jolla Village Drive, Suite 800
San Diego CALIFORNIA 92122 US
CEO: Charles P. Theuer
Employees: 18
Company Website: https://www.traconpharma.com/
Phone: 18585500780
The current stock price of TCON is 1.43 USD. The price decreased by -1.38% in the last trading session.
The exchange symbol of TRACON PHARMACEUTICALS INC is TCON and it is listed on the Nasdaq exchange.
TCON stock is listed on the Nasdaq exchange.
9 analysts have analysed TCON and the average price target is 31.11 USD. This implies a price increase of 2075.52% is expected in the next year compared to the current price of 1.43. Check the TRACON PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
TRACON PHARMACEUTICALS INC (TCON) has a market capitalization of 3.83M USD. This makes TCON a Nano Cap stock.
TRACON PHARMACEUTICALS INC (TCON) currently has 18 employees.
TRACON PHARMACEUTICALS INC (TCON) has a support level at 1.23 and a resistance level at 1.5. Check the full technical report for a detailed analysis of TCON support and resistance levels.
The Revenue of TRACON PHARMACEUTICALS INC (TCON) is expected to decline by -100% in the next year. Check the estimates tab for more information on the TCON EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
TCON does not pay a dividend.
TRACON PHARMACEUTICALS INC (TCON) will report earnings on 2024-08-12, after the market close.
The PE ratio for TRACON PHARMACEUTICALS INC (TCON) is 0.16. This is based on the reported non-GAAP earnings per share of 9.07 and the current share price of 1.43 USD. Check the full fundamental report for a full analysis of the valuation metrics for TCON.
ChartMill assigns a fundamental rating of 4 / 10 to TCON. The financial health of TCON is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months TCON reported a non-GAAP Earnings per Share(EPS) of 9.07. The EPS increased by 808.59% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 14.39% | ||
ROA | 18.69% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 80% to TCON. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -142.4% and a revenue growth -100% for TCON